Cargando…

DCE-MRI for Early Prediction of Response in Hepatocellular Carcinoma after TACE and Sorafenib Therapy: A Pilot Study

OBJECTIVE: Dynamic contrast-enhanced MRI (DCE-MRI) can measure the changes in tumor blood flow, vascular permeability and interstitial and intravascular volume. The objective was to evaluate the efficacy of DCE-MRI in prediction of Barcelona Clinic Liver Cancer (BCLC) staging B or C hepatocellular c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saito, Kazuhiro, Ledsam, Joseph, Sugimoto, Katsutoshi, Sourbron, Steven, Araki, Yoichi, Tokuuye, Koichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ubiquity Press 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032464/ https://www.ncbi.nlm.nih.gov/pubmed/30039052 http://dx.doi.org/10.5334/jbsr.1278

Ejemplares similares

Intravoxel incoherent motion MRI as a biomarker of sorafenib treatment for advanced hepatocellular carcinoma: a pilot study
por: Shirota, Natsuhiko, et al.
Publicado: (2016)

3D analysis of apparent diffusion coefficient histograms in hepatocellular carcinoma: correlation with histological grade
por: Moriya, Tomohisa, et al.
Publicado: (2017)

The Prognosis of Hepatocellular Carcinoma Treated with Sorafenib in Combination with TACE
por: Kimura, Yusuke, et al.
Publicado: (2020)

Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression
por: Zou, Xinhua, et al.
Publicado: (2021)

Transarterial Chemoembolization (TACE) Plus Sorafenib Compared to TACE Alone in Transplant Recipients with Hepatocellular Carcinoma: An Institution Experience
por: Abdelrahim, Maen, et al.
Publicado: (2022)

Transarterial Chemoembolization (TACE) plus Sorafenib Versus TACE for Intermediate or Advanced Stage Hepatocellular Carcinoma: A Meta-Analysis
por: Zhang, Leida, et al.
Publicado: (2014)

Diffuse Recurrence of Hepatocellular Carcinoma After Liver Resection: Transarterial Chemoembolization (TACE) Combined With Sorafenib Versus TACE Monotherapy
por: Yao, Wang, et al.
Publicado: (2020)

Effectiveness of c-TACE Combined With Sorafenib Versus c-TACE Monotherapy in Advanced Hepatocellular Carcinoma: A Retrospective Study
por: Liu, Shanshan, et al.
Publicado: (2023)

Transarterial Chemoembolization (TACE) Combined with Sorafenib versus TACE Alone for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Study
por: Ren, Baosheng, et al.
Publicado: (2019)

Efficacy and safety of TACE in combination with sorafenib for the treatment of TACE-refractory advanced hepatocellular carcinoma in Chinese patients: a retrospective study
por: Wu, Jianbing, et al.
Publicado: (2017)

Efficacy and safety analysis of TACE + Donafenib + Toripalimab versus TACE + Sorafenib in the treatment of unresectable hepatocellular carcinoma: a retrospective study
por: Lu, Haohao, et al.
Publicado: (2023)

A Combination of Sorafenib, an Immune Checkpoint Inhibitor, TACE and Stereotactic Body Radiation Therapy versus Sorafenib and TACE in Advanced Hepatocellular Carcinoma Accompanied by Portal Vein Tumor Thrombus
por: Zhang, Zeyu, et al.
Publicado: (2022)

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
por: Kudo, Masatoshi, et al.
Publicado: (2020)

Transarterial chemoembolization (TACE) combined with apatinib versus TACE combined with sorafenib in advanced hepatocellular carcinoma patients: a multicenter retrospective study
por: Qiu, Zhiyu, et al.
Publicado: (2021)

Early Diagnosis Value of DCE-MRI Hemodynamic Parameters in Hepatocellular Carcinoma
por: Mu, Xixi, et al.
Publicado: (2022)

Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis
por: Zhang, XiuPing, et al.
Publicado: (2017)

TACE Plus Lenvatinib Versus TACE Plus Sorafenib for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Prospective Cohort Study
por: Yang, Biao, et al.
Publicado: (2021)

Changing TACTICS in intermediate HCC: TACE plus sorafenib
por: Radu, Pompilia, et al.
Publicado: (2020)

Identifying optimal candidates of transarterial chemoembolization (TACE) vs. sorafenib in patients with unresectable hepatocellular carcinoma
por: Zhao, Shoujie, et al.
Publicado: (2020)

TACE-Sorafenib With Thermal Ablation Has Survival Benefits in Patients With Huge Unresectable Hepatocellular Carcinoma
por: Wu, Ying, et al.
Publicado: (2020)

Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory Hepatocellular Carcinoma: A Retrospective Study
por: Zheng, Liyun, et al.
Publicado: (2021)

The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma
por: Qu, Xu-Dong, et al.
Publicado: (2012)

Comparing the effectiveness and safety of Sorafenib plus TACE with Apatinib plus TACE for treating patients with unresectable hepatocellular carcinoma: a multicentre propensity score matching study
por: Yin, Liang, et al.
Publicado: (2023)

Early Changes in DCE-MRI Biomarkers May Predict Survival Outcomes in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: Two Prospective Phase II Trials
por: Chen, Bang-Bin, et al.
Publicado: (2021)

Prospective study of TACE combined with sorafenib vs TACE combined with (125)I seed implantation in the treatment of hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulas
por: Zhao, Xiao-Hui, et al.
Publicado: (2022)

Irradiation stent with (125)I plus TACE versus sorafenib plus TACE for hepatocellular carcinoma with major portal vein tumor thrombosis: a multicenter randomized trial
por: Lu, Jian, et al.
Publicado: (2023)

TACE versus TACE + entecavir versus TACE + tenofovir in the treatment of HBV associated hepatocellular carcinoma
por: Lu, Haohao, et al.
Publicado: (2023)

Combination Therapy after TACE for Hepatocellular Carcinoma with Macroscopic Vascular Invasion: Stereotactic Body Radiotherapy versus Sorafenib
por: Shen, Lujun, et al.
Publicado: (2018)

Transarterial chemoembolization (TACE) plus sorafenib: a real winning combination?
por: Adhoute, Xavier, et al.
Publicado: (2020)

DCE-MRI-based radiomics in predicting angiopoietin-2 expression in hepatocellular carcinoma
por: Zheng, Jing, et al.
Publicado: (2023)

The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE
por: Kim, Jung Hee, et al.
Publicado: (2017)

Efficacy and Safety of TACE Combined with Regorafenib Plus PD-1 Inhibitor in the Treatment of Hepatocellular Carcinoma After Sorafenib Resistance
por: Zou, Xinhua, et al.
Publicado: (2023)

Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis
por: Zhao, Shu, et al.
Publicado: (2022)

Transarterial Chemoembolization of Child-A hepatocellular carcinoma: Drug-eluting bead TACE (DEB TACE) vs. TACE with Cisplatin/Lipiodol (cTACE)
por: Wiggermann, Philipp, et al.
Publicado: (2011)

Important CT findings for prediction of severe appendicitis: involvement of retroperitoneal space
por: Kitaoka, Kumiko, et al.
Publicado: (2014)

Tumor Hypervascularity and hand-foot-skin reaction predict better outcomes in combination treatment of TACE and Sorafenib for intermediate hepatocellular carcinoma
por: Wang, Enxin, et al.
Publicado: (2019)

Clinical outcomes of hepatocellular carcinoma patients after hepatectomy treated with TACE in combination with sorafenib: a propensity score matched analysis
por: Li, Yujie, et al.
Publicado: (2023)

Comparison of Ultrafast Dynamic Contrast-Enhanced (DCE) MRI with Conventional DCE MRI in the Morphological Assessment of Malignant Breast Lesions
por: Ohashi, Akane, et al.
Publicado: (2023)

Combination Therapy of Sorafenib and TACE for Unresectable HCC: A Systematic Review and Meta-Analysis
por: Liu, Lei, et al.
Publicado: (2014)

The feasibility of superparamagnetic iron oxide–enhanced magnetic resonance imaging for assessing liver lesions in patients with contraindications for iodine CT contrast media or gadolinium-based MR contrast media: a retrospective case-control study
por: Kurata, Chishio, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_giqqsjkh190jkldoar6imgoat6